uniQure N.V.
uniQure N.V. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 22, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 11 months based on the most recent reported cash position and quarterly operating burn as of 2026-03-31.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 22, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 30, 2026 | AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | Trial Milestone | Phase 1/Phase 2 |
| December 1, 2027 | Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease | Trial Milestone | Phase 1/Phase 2 |
| March 15, 2029 | Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2029 | Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease | Trial Milestone | Phase 1/Phase 2 |
Track QURE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open QURE in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.